CN1704066A - 异落叶松树脂醇的药物用途 - Google Patents
异落叶松树脂醇的药物用途 Download PDFInfo
- Publication number
- CN1704066A CN1704066A CN 200510075357 CN200510075357A CN1704066A CN 1704066 A CN1704066 A CN 1704066A CN 200510075357 CN200510075357 CN 200510075357 CN 200510075357 A CN200510075357 A CN 200510075357A CN 1704066 A CN1704066 A CN 1704066A
- Authority
- CN
- China
- Prior art keywords
- endotoxemia
- acute
- isolarisiresinol
- medicine
- prostration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037487 Endotoxemia Diseases 0.000 claims abstract description 40
- 239000003814 drug Substances 0.000 claims abstract description 13
- 206010040047 Sepsis Diseases 0.000 claims abstract description 10
- 201000010099 disease Diseases 0.000 claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 208000006454 hepatitis Diseases 0.000 claims abstract description 8
- 210000000056 organ Anatomy 0.000 claims abstract description 8
- 230000001154 acute effect Effects 0.000 claims abstract description 6
- 231100000283 hepatitis Toxicity 0.000 claims abstract description 6
- 208000015181 infectious disease Diseases 0.000 claims abstract description 4
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 4
- 241000701022 Cytomegalovirus Species 0.000 claims abstract description 3
- 206010035664 Pneumonia Diseases 0.000 claims abstract description 3
- 210000003445 biliary tract Anatomy 0.000 claims abstract description 3
- 238000002512 chemotherapy Methods 0.000 claims abstract description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims abstract description 3
- 208000003243 intestinal obstruction Diseases 0.000 claims abstract description 3
- 208000013223 septicemia Diseases 0.000 claims abstract description 3
- 238000002054 transplantation Methods 0.000 claims abstract description 3
- 241001529453 unidentified herpesvirus Species 0.000 claims abstract description 3
- 238000002360 preparation method Methods 0.000 claims description 13
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims description 5
- 206010040070 Septic Shock Diseases 0.000 claims description 5
- 206010049771 Shock haemorrhagic Diseases 0.000 claims description 5
- 230000036303 septic shock Effects 0.000 claims description 5
- 208000007788 Acute Liver Failure Diseases 0.000 claims description 3
- 206010000804 Acute hepatic failure Diseases 0.000 claims description 3
- 230000004064 dysfunction Effects 0.000 claims description 3
- 208000002720 Malnutrition Diseases 0.000 claims description 2
- 208000010643 digestive system disease Diseases 0.000 claims description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 2
- 230000001071 malnutrition Effects 0.000 claims description 2
- 235000000824 malnutrition Nutrition 0.000 claims description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 claims description 2
- 206010042772 syncope Diseases 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 abstract description 7
- 230000000968 intestinal effect Effects 0.000 abstract description 6
- 206010052428 Wound Diseases 0.000 abstract description 5
- 230000035939 shock Effects 0.000 abstract description 5
- 206010016256 fatigue Diseases 0.000 abstract 4
- 208000018299 prostration Diseases 0.000 abstract 4
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 230000008383 multiple organ dysfunction Effects 0.000 abstract 1
- 206010040560 shock Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 235000000112 undernutrition Nutrition 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 42
- 150000001875 compounds Chemical class 0.000 description 25
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
- 239000011347 resin Substances 0.000 description 17
- 229920005989 resin Polymers 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 16
- NOEGNKMFWQHSLB-UHFFFAOYSA-N 5-hydroxymethylfurfural Chemical compound OCC1=CC=C(C=O)O1 NOEGNKMFWQHSLB-UHFFFAOYSA-N 0.000 description 15
- RJGBSYZFOCAGQY-UHFFFAOYSA-N hydroxymethylfurfural Natural products COC1=CC=C(C=O)O1 RJGBSYZFOCAGQY-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 239000002158 endotoxin Substances 0.000 description 13
- 238000000605 extraction Methods 0.000 description 13
- 239000007788 liquid Substances 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 11
- 241000218652 Larix Species 0.000 description 11
- 235000005590 Larix decidua Nutrition 0.000 description 11
- 239000000284 extract Substances 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 10
- 239000010231 banlangen Substances 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- -1 organic acid chemical compound Chemical class 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000003208 petroleum Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical class O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 229920005610 lignin Polymers 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- JMSVCTWVEWCHDZ-UHFFFAOYSA-N syringic acid Chemical compound COC1=CC(C(O)=O)=CC(OC)=C1O JMSVCTWVEWCHDZ-UHFFFAOYSA-N 0.000 description 4
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 208000010718 Multiple Organ Failure Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000003463 adsorbent Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003729 cation exchange resin Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002481 ethanol extraction Methods 0.000 description 3
- 238000003810 ethyl acetate extraction Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001047 pyretic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001986 anti-endotoxic effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 150000004668 long chain fatty acids Chemical class 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- YIBXWXOYFGZLRU-UHFFFAOYSA-N syringic aldehyde Natural products CC12CCC(C3(CCC(=O)C(C)(C)C3CC=3)C)C=3C1(C)CCC2C1COC(C)(C)C(O)C(O)C1 YIBXWXOYFGZLRU-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- OGFXBIXJCWAUCH-KPHUOKFYSA-N (+)-isolariciresinol Chemical compound C1([C@@H]2[C@@H](CO)[C@H](CO)CC=3C=C(C(=CC=32)O)OC)=CC=C(O)C(OC)=C1 OGFXBIXJCWAUCH-KPHUOKFYSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010056375 Bile duct obstruction Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 241000334154 Isatis tinctoria Species 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010053879 Sepsis syndrome Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 102000011759 adducin Human genes 0.000 description 1
- 108010076723 adducin Proteins 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000006315 carbonylation Effects 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000005555 hypertensive agent Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- QNLOWBMKUIXCOW-UHFFFAOYSA-N indol-2-one Chemical group C1=CC=CC2=NC(=O)C=C21 QNLOWBMKUIXCOW-UHFFFAOYSA-N 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- OEZZQOVAJDAVSJ-UHFFFAOYSA-N isolariciresinol Natural products COc1cc(ccc1O)C1C(CO)C(CO)Cc2cc(O)c(OC)cc12 OEZZQOVAJDAVSJ-UHFFFAOYSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
不同工艺提取组分80%乙醇提取部位阳离子交换树脂流出液醇提取部位大孔吸附树脂10%-50%醇洗脱部位氯仿萃取部位乙酸乙酯萃取部位正丁醇萃取部位 | 存活时间(h) | 存活率(%) | X2检验(X2≥3.84)22.926.865.239.9211.3213.44 | T检验(P≤0.05)4.04*10-93.33*10-39.60*10-33.80*10-44.04*10-53.17*10-5 | ||
对照组31.1538.9031.1524.5733.8625.62 | 给药组67.4559.3347.2045.5861.5655.40 | 对照组8/3212/308/324/349/305/30 | 给药组28/3223/3018/3217/3423/3020/30 |
给药部位编号给药部位1给药部位2给药部位3给药部位4给药部位5给药部位6背景溶液7 | 各部位所占比例(重量比) 动物试验数据 | |||||
5-HMF17.0017.0051.000.000.000.000.00 | 异落叶松树醇酯1.001.000.001.001.500.000.00 | 1-N-甲氧基-2-氧-吲哚-3-乙酰胺15.00.000.007.50.0030.00.00 | 药液pH值4.002.802.503.803.504.503.50 | X2检验(X2≥3.84)20.4313.084.194.223.954.190.00 | T检验(P≤0.05)5.16*10-97.04*10-50.050.010.000.050.00 |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200510075357 CN1286469C (zh) | 2003-01-30 | 2003-01-30 | 异落叶松树脂醇的药物用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200510075357 CN1286469C (zh) | 2003-01-30 | 2003-01-30 | 异落叶松树脂醇的药物用途 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 03102065 Division CN1251698C (zh) | 2003-01-30 | 2003-01-30 | 一种治疗内毒素血症的板蓝根提取物和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1704066A true CN1704066A (zh) | 2005-12-07 |
CN1286469C CN1286469C (zh) | 2006-11-29 |
Family
ID=35575788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200510075357 Expired - Fee Related CN1286469C (zh) | 2003-01-30 | 2003-01-30 | 异落叶松树脂醇的药物用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1286469C (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102614206A (zh) * | 2011-01-31 | 2012-08-01 | 澳门科技大学 | 7S,8R,8′R-(+)-落叶松树脂醇-4,4′-二-O-β-D-吡喃葡萄糖苷在制药中的应用 |
CN107079906A (zh) * | 2017-06-30 | 2017-08-22 | 重庆市碚圣医药科技股份有限公司 | 一种植物源杀虫剂及其制备方法和用途 |
-
2003
- 2003-01-30 CN CN 200510075357 patent/CN1286469C/zh not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102614206A (zh) * | 2011-01-31 | 2012-08-01 | 澳门科技大学 | 7S,8R,8′R-(+)-落叶松树脂醇-4,4′-二-O-β-D-吡喃葡萄糖苷在制药中的应用 |
CN107079906A (zh) * | 2017-06-30 | 2017-08-22 | 重庆市碚圣医药科技股份有限公司 | 一种植物源杀虫剂及其制备方法和用途 |
CN107079906B (zh) * | 2017-06-30 | 2020-09-15 | 重庆市碚圣医药科技股份有限公司 | 一种植物源杀虫剂及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN1286469C (zh) | 2006-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1286455C (zh) | 5-羟甲基糠醛的药物用途 | |
CN1251698C (zh) | 一种治疗内毒素血症的板蓝根提取物和用途 | |
CN111297859A (zh) | 钩吻素子在制备治疗肝细胞损伤药物中的应用 | |
CN1286469C (zh) | 异落叶松树脂醇的药物用途 | |
CN1965853A (zh) | 龙胆苦苷在抗病毒药物中的应用 | |
WO2023236797A1 (zh) | Hangtaimycin衍生物及其制备方法和应用 | |
CN1056751C (zh) | 知石清解注射液 | |
CN1286466C (zh) | 地乌皂苷w3在治疗风湿类疾病药物制剂中的应用 | |
CN1709417A (zh) | 一种杏香兔耳风提取物及其制备方法 | |
CN113861135B (zh) | 白木香四醇及其药物组合物与其制备方法和应用 | |
CN1698606A (zh) | 喹诺里西啶类生物碱在制备抗乙肝病毒药物中的用途 | |
CN1141101C (zh) | 治疗乙肝的药物及其制备方法 | |
CN1201737C (zh) | 千金藤素在制备抗sars病毒药物中的应用 | |
CN101062046A (zh) | 一种皂苷类成分的医学用途 | |
CN1193766C (zh) | 治疗肝炎的栀子总甙组合物及其制备方法 | |
CN1181855C (zh) | 贯叶连翘提取物的制备方法 | |
CN1939327A (zh) | 柳川鱼苷、蒙花苷及其组合物的制药用途 | |
CN1081922C (zh) | 含人参皂甙Re组分的药物组合物,其制备方法及应用 | |
CN1724527A (zh) | 梣酮作为肝病治疗药物的应用 | |
CN1872101A (zh) | 具抗病毒作用的小紫金牛提取物及其提取方法和应用 | |
CN1839867A (zh) | 具有清热、泻火和解毒作用的药物组合物 | |
CN1188118C (zh) | 一种预防或治疗癌症的药物及其用途 | |
CN1148193C (zh) | 低聚寡糖在抗应激脑损伤中的用途 | |
CN1616038A (zh) | 一种野菊花冻干粉针剂及其制备方法 | |
CN1242755C (zh) | 一种中药提取物及其制备工艺和在制药中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HEILONGJIANG TIANYI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: PU WENYING Effective date: 20100928 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100011 TO: 163316 |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100928 Address after: 163316 Jianshe Road high tech Zone, Heilongjiang, No. 245, Patentee after: Heilongjiang Tianyi Pharmaceutical Co., Ltd. Address before: 100011 Beijing Dongcheng District Andingmen Street No. 21 Building No. 10 15-8 Patentee before: Pu Wenying |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061129 Termination date: 20150130 |
|
EXPY | Termination of patent right or utility model |